Edwards Lifesciences Corporation EW recently gained CE Mark for its PASCAL Precision transcatheter valve repair system used to treat mitral and tricuspid regurgitation. The PASCAL Precision system is ...

JP Morgan upgraded Edwards Lifesciences (EW) to overweight from neutral highlighting accelerating growth in its transcatheter aortic valve replacement (TAVR) division and strength in its transcatheter ...

2025 Financial Outlook: $5.6-$6 billion in total sales; adjusted EPS of $2.40-$2.50. Therapy Growth: TAVR sales projected at $4.1-$4.4 billion (5%-7% growth); TMTT ...

Narrow-moat Edwards Lifesciences kicked off the year with solid results, and the slight adjustments we’ve made to incorporate stronger growth in the transcatheter mitral and tricuspid business (TMTT) ...